Science Corporation closes oversubscribed $230M Series C — first BCI company targeting commercial launch as vision restorer
Summary
Science Corporation closed an oversubscribed $230M Series C in March 2026 to fund commercialization of PRIMA in Europe and expansion of Biohybrid neural interface, Vessel perfusion platform, MEMS Foundry, and BCI Ecosystem businesses. PRIMA was the only treatment in clinical trials to successfully restore form vision to AMD patients, published in NEJM October 2025 and featured on the cover of Time. Science is first to submit CE mark for a BCI vision restoration product and holds FDA Breakthrough Device Designation.
Why it matters
Science Corporation reaching commercial readiness before Neuralink or Synchron — because their retinal BCI doesn't require brain surgery — validates the sensory BCI market thesis first. PRIMA on the cover of Time means consumer awareness is far ahead of regulatory approval, creating demand-pull commercialization rather than supply-push physician adoption. Science's parallel BCI Ecosystem business also positions them as an industry platform for future BCI partnerships.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial